Want to know if this job is worth applying to?
Basel, Basel-Stadt, Schweiz/Suisse/Svizzera/Svizra
Onsite
At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections, where you are valued, accepted and respected for who you are, allowing you to thrive both personally and professionally. This is how we aim to prevent, stop and cure diseases and ensure everyone has access to healthcare today and for generations to come. Join Roche, where every voice matters.
Pharmaceutical & Solid State Development is part of Pharma Technical Development and situated in Basel, Switzerland.
Our key expertise is the development of robust and economic processes for drug substances with tailor-made solid state properties and patient centric formulations for the synthetic molecule portfolio of projects from early clinical studies to commercialization. We advance the design and delivery of transformative medicines by combining particle engineering, characterization, and formulation development - ensuring optimal drug performance, manufacturability, and patient-centric solutions from molecule to medicine.
As an intern you will support the department Pharmaceutical & Solid State Development in the development of drug delivery technologies such as amorphous solid dispersions for oral delivery of bRo5 molecules.
● Review of the relevant literature applicable to the project
● Training in relevant SOPs and manufacturing/analytical equipment
● Manufacturing and characterization of spray dried amorphous solid dispersions
● Preparation and characterization of solid dosage forms
● Regular discussion of project progress with supervisors and planning of next steps
● Writing of final report
You are a University student (or you graduated within 12 months prior to the start date) preferably in the subject of Pharmaceutical Sciences, Pharmaceutical Technology or similar subjects and have an interest in formulation and manufacturing. Furthermore, you are interested in using and sharing your knowledge as part of your Internship in a modern working environment.
Your further profile for this position:
● Reliable and accurate working style in a non-GMP environment
● Team-oriented and decision-making personality
● Self-sufficient, problem solving-oriented work habits
● Good knowledge of MS-Office (Word, Excel, PowerPoint)
● Proficiency in English, German is a plus
This internship opportunity is one of a number of positions we offer in the department per semester and is suitable for writing a Master/Diploma thesis.
The interviews will take place on an interview day with all considered candidates and representatives of the department.
Your complete application includes the following documents:
● A Current CV and a Motivation Letter
● A certificate of enrollment (if you are currently studying)
● For Non-EU/EFTA citizens: Due to regulations, you must provide a certificate issued by your university stating that an Internship is mandatory for your studies and you must be enrolled during the entire duration of the internship
● The RiSM task (see below)
The application deadline is 23.08.2026. All successful final candidates will be invited to a virtual interview day which will take place on 14.10.2026.
The Internship will start in October to December 2027 and has a duration of 9 to 12 months, please indicate your preferred start date in your application.
More information about the Roche Internship program in Synthetic Molecules (RiSM) and other opportunities within this program you can find here.
Are you ready to apply? We are looking for someone who thinks beyond the job offered - someone who knows that this position can be a rare springboard to many other opportunities.
Assume you are a formulation scientist that has the task to develop a poorly water soluble drug (MW 923.43 g/mol, LogP≈ 5.5 - 7.5. Solubility in DMSO: up to 100 mg/mL, Ethanol: up to ≈ 3-6 mg/mL) for the treatment of head-neck-cancer. What are your considerations with respect to the formulation, manufacturing technology and dosage form? Please use the information provided
in the following article (Dana E. Moseson, Trong Bien Tran, Bharathi Karunakaran, Rohan Ambardekar, Tze Ning Hiew, Trends in amorphous solid dispersion drug products approved by the U.S. Food and Drug Administration between 2012 and 2023, International Journal of Pharmaceutics: X, Volume 7, 2024, 100259, https://doi.org/10.1016/j.ijpx.2024.100259.) to
answer those questions. We anticipate receiving your answers in the form of a slide deck suitable for presentation to a project team (maximum of 5 slides, PDF format) alongside your application.
A healthier future drives us to innovate. Together, more than 100’000 employees across the globe are dedicated to advance science, ensuring everyone has access to healthcare today and for generations to come. Our efforts result in more than 26 million people treated with our medicines and over 30 billion tests conducted using our Diagnostics products. We empower each other to explore new possibilities, foster creativity, and keep our ambitions high, so we can deliver life-changing healthcare solutions that make a global impact.
Let’s build a healthier future, together.
Roche is an Equal Opportunity Employer.